Does Wegovy Increase Depression Risk?
Wegovy (semaglutide) carries a warning for potential mental health side effects, including depression, based on clinical trials and post-marketing reports. The prescribing label notes suicidal thoughts or behavior occurred in 0.3% of patients (6 out of 1966) during trials, compared to 0.1% (1 out of 967) on placebo—though rates were low overall.[1] Real-world data from sources like the FDA's FAERS database show higher reports of depression and suicidality with GLP-1 agonists like semaglutide, prompting an ongoing FDA investigation as of 2024 into whether these drugs elevate risks beyond background rates.[2][3]
Patients with a history of depression or mental health issues face higher vulnerability; the label advises monitoring and discontinuation if mood changes emerge.[1]
How Common Is Depression on Wegovy?
- Clinical trial data: Depression reported in 1-2% of Wegovy users across trials (e.g., STEP 1 trial: 1.8% vs. 1.3% placebo).[4]
- Post-approval: Anecdotal surges in reports, with some analyses estimating 1.5-3 times higher odds of depression diagnosis shortly after starting GLP-1s versus other weight-loss drugs.[5] A 2024 study in JAMA found no overall increase in suicidal ideation but noted signals in patients with prior psychiatric conditions.[6]
Risk appears dose-dependent and more pronounced early in treatment.
Why Might Wegovy Cause Depression?
Rapid weight loss, hormonal shifts (e.g., GLP-1 effects on brain reward centers), or interactions with antidepressants may contribute. Some patients report "Wegovy mood swings" tied to appetite suppression altering dopamine signaling. No causal mechanism is proven, but brain imaging studies show GLP-1s influence mood-regulating areas like the hypothalamus.[7]
What Do Patients Report About Mood Changes?
Forums like Reddit and Drugs.com highlight user experiences: ~10-20% mention low mood, anxiety, or depression starting weeks into treatment, often resolving after dose adjustment or stopping. Common triggers include fatigue from calorie restriction or GI side effects amplifying emotional lows.[8]
Who Is at Higher Risk?
- Pre-existing depression, anxiety, or bipolar disorder.
- Younger adults (under 40) or those on high doses (2.4 mg weekly).
- Concurrent use with SSRIs or other psych meds—monitor for worsening.[1][9]
Black box warning absent, but EU label added "risk of depression" in 2023.[10]
How Does Wegovy Compare to Ozempic or Mounjaro?
| Drug | Depression Rate (Trials) | Suicidality Signal |
|------|---------------------------|---------------------|
| Wegovy (semaglutide 2.4mg) | 1-2% | Low (0.3%)[4] |
| Ozempic (semaglutide 1-2mg) | 0.5-1.5% | Similar[1] |
| Mounjaro (tirzepatide) | 1-3% | Emerging reports[11] |
All GLP-1s share mood risks; tirzepatide may edge higher due to dual GIP action.[12]
What Should You Do If Depression Starts?
Stop Wegovy and seek medical help immediately, especially for suicidal thoughts. Providers recommend baseline mental health screening before prescribing. Alternatives like bupropion (with naltrexone) target weight loss without GLP-1 mood risks.[13]
[1]: FDA Wegovy Label
[2]: FDA GLP-1 Safety Update
[3]: FAERS Database Query
[4]: STEP 1 Trial (NEJM)
[5]: Nature Medicine Analysis (2024)
[6]: JAMA Network Open (2024)
[7]: Neuropsychopharmacology Review
[8]: Drugs.com Wegovy Reviews
[9]: Endocrine Society Guidelines
[10]: EMA Semaglutide Update
[11]: SURMOUNT Trials (NEJM)
[12]: Diabetes Care Comparison
[13]: Contrave Label